Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Low Serum Creatinine Associated with Diabetes Risk

By LabMedica International staff writers
Posted on 02 May 2019
Creatinine is the only metabolite of creatine phosphate in the skeletal muscle and under the steady state; it is created at a relatively constant rate by the body depending on the total skeletal muscle mass.

Because of the close association between muscle mass and creatinine (correlation coefficient equal to or greater than 0.7), serum creatinine is also used as an inexpensive, easily available surrogate of muscle mass when the kidney functions are stable and protein intake is normal.

Scientists at the National Center for Global Health and Medicine (Tokyo, Japan) and their colleagues conducted a prospective analysis using data from 31,343 men aged between 20 to 64 years without diabetes at baseline from the Japan Epidemiology Collaboration on Occupational Health Study. More...
Participants were followed for a median of 7.7 years until March 2017 and separated into four groups based on baseline serum creatinine levels: less than 0.7 mg/dL (n = 1,492; mean age, 44.9 years), 0.7 mg/dL to 0.79 mg/dL (n = 6,405; mean age, 42.6 years), 0.8 mg/dL to 0.89 mg/dL (n = 10,848; mean age, 42.1 years) and 0.9 mg/dL to 1.2 mg/dL (n = 12,598; mean age, 43.6 years).

The team assessed the levels of serum creatinine using the enzymatic method and identified 2,509 cases of diabetes in the study cohort. The plasma glucose was measured using either the enzymatic or glucose oxidase peroxidative electrode method. HbA1c was measured using a latex agglutination immunoassay, high-performance liquid chromatography, or the enzymatic method. They defined diabetes as either HbA1c levels ≥6.5%, random glucose levels ≥200 mg/dL, fasting glucose levels ≥126 mg/dL or receiving antidiabetic treatment. The participants who met any of the aforementioned conditions during follow up were treated as incident cases of type 2 diabetes.

Men with serum creatinine levels of less than 0.7 mg/dL were at the highest risk for the condition (HR = 1.56)) compared with men with levels of 0.9 mg/dL to 1.2 mg/dL even after adjustments for age, smoking status, BMI, hypertension and dyslipidemia. Men with serum creatinine levels of 0.7 mg/dL to 0.79 mg/dL (HR = 1.22 and 0.8 mg/dL to 0.89 mg/dL (HR = 1.06) also were at higher fully adjusted risk compared with men with levels of 0.9 mg/dL to 1.2 mg/dL. The scientists further observed that men who were aged 45 years or older had higher risk in all creatinine groups compared with men who were younger than 45 years.

The team concluded that in their study based on repeated measurements of serum creatinine shows that low serum creatinine is associated with an increased risk of diabetes. Screening serum creatinine levels can be used to identify those at a high risk of diabetes. Huanhuan Hu, PhD, the lead author of study, said, “Skeletal muscle is a primary target for insulin action. Thus, decreased skeletal muscle mass could potentially trigger insulin resistance, which is an underlying mechanism of diabetes.” The study was published originally published on February 12, 2019, in the Journal of Diabetes Investigation.

Related Links:
National Center for Global Health and Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.